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Abstract.
Background: Opioids are used with increasing frequency. Elderly with dementia are prescribed opioids more frequent than
elderly without. One possible explanation is that opioids may be used not only to treat pain but also behavioral symptoms.
Objective: To test the hypothesis that strong opioid use, especially transdermal formulations, had increased, especially in
elderly with dementia, in parallel with a decrease in antipsychotic use.
Methods: Population-based cross-sectional study conducted using nationwide Danish registers with data on Denmark’s entire
elderly population age ≥65 (2000: n = 802,106; 2015: n = 1,056,476). The registers were used to identify elderly with and
without dementia and filled prescriptions for opioids and antipsychotics. Annual prevalence of opioid and antipsychotic use
from 2000–2015 was calculated.
Results: Prevalence of opioid use increased by 35% (24.2 to 32.5%) among elderly with dementia and by 13% among elderly
without (14.9 to 16.8%) from 2000–2015. The disproportionate increase in opioid use among elderly with dementia was
mainly driven by an increase in strong opioids (dementia: 11.7 to 23.1%; without dementia: 5.9 to 7.4%). Use of antipsychotics
decreased during the same period (dementia: 31.3 to 19.3%; no dementia: 4.5 to 2.7%).
Conclusion: From 2000–2015, use of opioids among the elderly increased with a disproportionately higher increase among
elderly with dementia. The parallel decrease in the use of antipsychotics may suggest that opioids to some extent have replaced
antipsychotics in managing behavioral symptoms, despite safety concerns and lack of evidence for effect of opioids. Future
research should focus on potential risks associated with increased opioid use.
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INTRODUCTION
Behavioral symptoms, such as psychosis, aggres-
sion, agitation, and wandering, affect nearly all
patients with dementia at some point in time
[1] and are very distressing [2]. The causes of
behavioral symptoms include biological (e.g., under-
lying pathology, medication side effects, infections,
pain), psychological, and environmental factors [3].
Antipsychotics are often prescribed to treat behav-
ioral symptoms but have been associated with serious
adverse events and increased mortality, particularly
in elderly with dementia [4, 5], leading to safety
warnings and regulations worldwide [6–8]. Thus,
the focus on appropriate management of behavioral
symptoms has increased, with screening for physi-
cal and environmental causes prior to initiation of
antipsychotics. One hypothesis is that untreated pain
can lead to behavioral symptoms and it has been sug-
gested that analgesics (opioids or paracetamol) may
also be used to treat the symptoms [9]. However,
opioids may be associated with severe side effects
[10–12] and should be used with caution. Thus,
replacing antipsychotics by opioids would be very
problematic in cases where practitioners do not make
a thorough workup to identify the cause of behavioral
symptoms.
In a recent register-based study of the entire elderly
Danish population, we reported that opioids were
used more frequently by elderly with dementia [13],
but the reason was unknown. Prior research has
investigated if a standardized stepwise protocol of
analgesics to treat agitation in nursing home residents
with moderate to severe dementia [9]. One possi-
ble explanation for the frequent use of opioids could
be that opioids were used to treat behavioral symp-
toms in general in elderly with dementia and not
only when thought to be caused by pain. One way
of examining this further is to investigate prescrip-
tion practices and examine changes in use of opioids
and antipsychotics over time. Danish registries are
unique with respect to capturing an entire population,
disclosing important information about prescription
practices relevant in an international context. Thus,
we aimed to investigate changes in use of opioids and
antipsychotics in elderly with and without demen-
tia in Denmark from 2000–2015. Our previous study
found that strong opioids, particularly transdermal
formulations (i.e., fentanyl and buprenorphine), were
used frequently. We wanted to test the hypothesis
that strong opioid use, especially transdermal for-
mulations, had increased, especially in elderly with
dementia, in parallel with a decrease in the use of
antipsychotics.
METHODS
Study design
This population-based cross-sectional study used
nationwide Danish registers. We calculated annual
prevalence of opioid and antipsychotic use. The
study was approved by the Danish Data Protection
Agency (ID no.: 2007-58-0015/30-0667), Statistics
Denmark, and the Danish Health and Medicines
Authority (ID no.: 6-8011-907/1). Danish law does
not require ethics committee approval or written
informed patient consent for register based studies.
The registers
In Denmark, all permanent residents are assigned
a personal identification number at birth or immi-
gration, making it possible to link demographic and
medical data from nationwide registers at an indi-
vidual level [14]. Denmark has a public healthcare
system, where all somatic hospital admissions and
visits to outpatient clinics and emergency rooms are
registered in the National Patient Registry [15], while
psychiatric admissions and outpatient visits are in
the Psychiatric Central Registry [16]. Data on all
dispensed prescription drugs is registered in the Dan-
ish National Prescription Registry according to the
Anatomical Therapeutic Chemical (ATC) classifica-
tion system [17] (for further details, see [13]).
Study population
The annual population was defined each year on
January 1 (from 2000 to 2015) and included all Dan-
ish residents age ≥65. Thus, an individual could be
included at multiple index dates following their 65th
birthday, if still alive. Elderly with dementia were
identified as in- and outpatients registered with a
dementia diagnosis (see Supplementary Table 1 for
diagnostic codes) and/or as individuals who had filled
at least one prescription for an anti-dementia drug
(ATC: N06D). Individuals diagnosed or prescribed
an anti-dementia drug before age 60 were excluded
from the population. The remaining elderly popula-
tion age ≥65 without dementia formed the reference
population (for further details, see [18]). Time since
diagnosis was applied as a surrogate marker of sever-
ity of illness.
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Medication use
A user of a drug was defined as an individual who
had filled at least one prescription within a year. In
Denmark, opioids are only available by prescription
from a physician and can only be dispensed once
per prescription. Opioids (N02A) were grouped as
strong opioids (morphine analogues (N02AA01-04),
oxycodone (N02AA05-55), pethidine (N02AB02),
fentanyl (N02AB03), buprenorphine (N02AE01),
and ketobemidone (N02AG02)) and weak opi-
oids ((codeine (N02AA59), dextropropoxyphene
(N02AC04), and tramadol (N02AX02)). Only fen-
tanyl (N02AB03) and buprenorphine (N02AE01) are
available as transdermal formulations, and these were
grouped as such. Antipsychotics (N05A) included
both first and second-generation but excluded lithium
(N05AN). Annual prevalence of all opioids, strong
opioids, weak opioids, transdermal formulations of
opioids, and antipsychotic use in elderly with and
without dementia was calculated annually according
to the population.
To evaluate the amount used in a given year, we cal-
culated equivalent doses of oral morphine and total
dose for each user (Supplementary Table 2). The
equianalgesic dose of morphine in one defined daily
dose (DDD) varies from opioid to opioid (see Supple-
mentary Table 2). The equianalgesic content of one
DDD does not reflect a suitable dose for an elderly
person, i.e., one DDD of oral morphine is 100 mg,
which is very high dose for an elderly. To calculate
duration of use, equianalgesic doses were calculated
and a daily dose equivalent of 30 mg of oral morphine
was assumed.
Comorbidity
Comorbidity was evaluated in the year prior to
the index date. Data from somatic and psychiatric
hospital contacts was used to identify comorbid
conditions. We evaluated potentially pain-causing
diseases (cancer, osteoporosis, arthritis recent frac-
ture, and diabetes) and comorbidity (vascular,
pulmonary, renal, and liver disease) that may affect
opioid use (Supplementary Table 3). The total
amount of comorbidity was evaluated using the
Charlson Comorbidity Index score, which com-
prises 19 chronic somatic diseases [19]. Psychiatric
comorbidity was defined as a registered diagnosis
of prior psychotic disorders (one of the follow-
ing diagnoses: schizophrenia, schizotypal, delusional
disorders (ICD-8:295.x9, 296.89, 297.x9, 298.29-
298.29-298.99, 299.04, 299.05, 299.09, 301.8;
ICD-10: F20-29); and, manic episode and bipolar
affective disorder (ICD-8:296.19, 296.39, 298.19;
ICD-10: F30-F31)) registered any time since 1969
before the dementia diagnosis. The total number of
different drugs used in the year prior was employed
as a surrogate marker of somatic disease not captured
by hospital admissions (ATC level 3).
Statistical analysis
Comparison of annual prevalence of drug use
requires independent observations. To achieve inde-
pendency between observations, the population was
divided into five-year age groups (age 65–69, 70–74,
75–79, 80–84, 85–89, 90–94, 95–99). Drug use in
each group was compared between 2000, 2005, 2010,
and 2015. Thus, an individual could not be rep-
resented at more than one time point in the same
age group. The reference year was 2000. A logistic
regression analysis was done separately for elderly
with and without dementia. A crude logistic regres-
sion analysis was performed with calendar year as
the independent variable. Age, sex, and individ-
ual comorbidity (i.e., cancer, osteoporosis, arthritis,
recent fracture, diabetes, vascular, pulmonary, renal,
and liver disease) were included in the multivariate
logistic regression analysis as potential confounders.
A p-value of <0.05 was considered statistically sig-
nificant. The data analysis was performed using SAS
statistical software, version 9.4 (SAS Institute Inc.,
Cary, NC, USA).
RESULTS
Study population
Figure 1 shows the selection of the population.
In 2000, there were 19,062 elderly age ≥65 with
dementia and 781,056 elderly without in Denmark,
which increased to 36,114 and 1,017,932, respec-
tively, in 2015. Table 1 lists the characteristics of the
study population. In both 2000 and 2015, elderly with
dementia were older, more likely to be female, used
more drugs, and suffered from more comorbidity than
elderly without.
Opioid use
Prevalence
Figure 2A and 2B present the annual prevalence
of use of all opioids. From 2000 to 2015, the preva-
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Fig. 1. Study population in 2000 (A) and 2015 (B).
Table 1
Characteristics of the Study Population in 2000 and 2015
2000 2015
Characteristic Patients with Elderly without Patients with Elderly without
Dementia Dementia Dementia Dementia
(n = 19,062) (n = 781,056) (n = 36,114) (n = 1,017,932)
Age, y 82.2 (77.0–87.1) 74.3 (69.4–80.1) 83.2 (77.5–88.2) 72.6 (68.7–78.8)
Women 12,865 (67.5%) 452,944 (58.0%) 22,849 (63.3%) 551,033 (54.1%)
Men 6,197 (32.5%) 328,112 (42.0%) 13,265, (36.7%) 466,899 (45.9%)
Time since diagnosis, y 2.0 (0.9–4.1) – 2.9 (1.3–5.4) –
Prior psychiatric disease 1,387 (7.3%) 10,146 (1.3%) 1,720 (4.8%) 15,065 (1.5%)
Number of drugs used in previous year 7 (4–10) 4 (2–7) 8 (6–11) 5 (2–8.)
Charlson Comorbidity Index* 1* (1-2) 0 (0–1) 2 (1–3) 0 (0–2)
Vascular disease 5,587 (29.3%) 97,361 (12.5%) 13,564 (37.6%) 208,635 (20.5%)
Lung disease 1,418 (7.4%) 51,883 (6.6%) 4,707 (13.0%) 100,019 (9.8%)
Kidney disease 271 (1.4%) 8,156 (1.0%) 1,708 (4.7%) 31,354 (3.1%)
Liver disease 206 (1.1%) 4.607 (0.6%) 675 (1.9%) 12,649 (1.2%)
Pain-specific comorbidity
Fracture in previous year 2,037 (10.7%) 26,258 (3.4%) 2,896 (8.0%) 27,916 (2.7%)
Osteoporosis 907 (4.8%) 17,429 (2.2%) 6,473 (17.9%) 106,880 (10.5%)
Cancer 2,113 (11.1%) 74,411 (9.5%) 7,396 (20.5%) 184,819 (18.2%)
Diabetes 1,158 (6.1%) 21,659 (2.8%) 4,214 (11.7%) 78,131 (7.7%)
Arthritis 2,573 (13.5%) 76,887 (9.8%) 6,984 (19.3%) 152,185 (15.0%)
∗Index calculated without dementia. †Numbers given as n (%) and median (25–75% interquartile range), as appropriate.
lence of opioid use increased by 35% (24.2 to 32.5%)
among elderly with dementia. The most noticeable
change occurred from 2004 and onwards, with the
highest prevalence in 2013 (33.6%). For elderly with-
out dementia, there was a 13% (14.9 to 16.8%)
increase in the prevalence of opioid use from 2000 to
2015, with the highest prevalence in 2010 (17.7%).
Figure 3 presents the results of a logistic regression
analysis comparing 2000 versus 2015 in five-year
age groups and stratified by dementia (Supplemen-
tary Table 4A, B). After adjusting for age, sex,
and comorbidity, use of opioids increased in all
age groups among elderly with dementia, with the
largest increase in 95-99-year-olds (odds ratio (OR)
(95% confidence interval (CI)): 2.05 (1.58–2.67)). In
elderly without dementia, there was a slight increase
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A
B
Fig. 2. Prevalence of opioid and antipsychotic use from 2000 to
2015 in elderly with dementia (A) and elderly without dementia
(B).
in age >90 (90–94: OR 95% CI: 1.15 (1.10–1.19);
95–99:1.30 (1.20–1.42)) and a slight decrease or no
change in the remaining groups. When comparing
CIs, there was a greater increase among elderly with
dementia in all age groups compared with elderly
without.
Treatment intensity
Figure 4 shows duration of opioid use. From 2000
to 2015, the median number of days treated with an
opioid increased by 39% (80 to 111 days) in elderly
with dementia but was unchanged for elderly without.
A
B
Fig. 3. Changes in Opioid Use in Elderly with Dementia (A) and
without Dementia (B). The figure shows the results of logistic
regression analyses comparing 2000 versus 2015 in five-year age
groups displaying adjusted odds ratios (ORs) and 95% confidence
intervals (CI). The adjusted ORs include adjustment for age, sex,
and all comorbidity.
Opioid subtypes
The increase in prevalence of opioid use in elderly
with dementia was mainly driven by an increase in
the use of strong opioids, which rose by 98% (11.7
to 23.1%). This increase was caused by a rise in the
use of transdermal formulations, which increased by
532% (2.7 to 14.0%). The increase in use of strong
opioids was lower among elderly without dementia
(25% increase; 5.9 to 7.4%), while use of transdermal
formulations increased by 90% (1.1 to 2.1%).
Antipsychotic use
Figure 2A and 2B show the annual prevalence of
antipsychotic use for elderly with and without demen-
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Fig. 4. Opioid treatment intensity. The figure shows the median
number of days treated with 30 mg of oral morphine per day in
elderly with and without dementia from 2000 to 2015.
tia (data from 2000 to 2012 previously published)
[18]. Antipsychotics decreased by 62% in elderly
with dementia during the period (31.3 to 19.3%), with
a marked decrease from 2004 and onwards.
DISCUSSION
The main finding of this study was that the preva-
lence of opioid use increased significantly from
2000 to 2015. The largest increase in opioid use
occurred among elderly with dementia, despite a
higher prevalence of opioid use in this group already
in 2000. The increase in opioid use in elderly with
dementia was mainly due to an increase in strong
opioid use. The use of transdermal formulations of
opioids, however, increased dramatically in elderly
with dementia. During the same period a significant
decrease in antipsychotic use was observed in elderly
with dementia.
To our knowledge, no previous studies have eval-
uated changes in opioid prescribing over time in
elderly with dementia and then compared the changes
with elderly without dementia. Previous studies
focused on nursing home residents in general and
not on elderly with dementia. A systematic review
on studies examining analgesic prescribing among
nursing home residents using data collected between
1996 and 2015 reported increased prescribing of opi-
oids and acetaminophen across nations over time
[20]. A small Finnish study analyzing opioid use
in 2003 and 2011 among institutionalized elderly
found an increase in opioid use from 11.8% in 2003
to 22.9% in 2011 [21]. Another study from Fin-
land investigated changes in opioid, paracetamol, and
antipsychotic use among nursing home residents and
similar to our study found that opioid use increased
(from 11.7% in 2003 to 30.2% in 2017) and antipsy-
chotic use decreased (from 42.7% in 2003 to 32.7%
in 2017). Furthermore, they studied use of paraceta-
mol and found that it increased from 34.3% in 2003
to 51.6% in 2017 [22]. A Norwegian study, evaluat-
ing analgesic prescribing in four different samples of
nursing home residents, found an increase in opioid
use from 10.9% in 2000 to 23.8% in 2011 [23]. In
the general population, increased opioid prescribing
has been reported in many countries [24, 25]. Thus,
our findings are in line with international prescribing
trends in the elderly but, surprisingly, the increase
was steeper among elderly with dementia despite a
higher baseline.
One may speculate about the reasons for the dis-
proportionate increase in opioid use among elderly
with dementia and possible explanations could be: 1)
increased awareness of and attention given to pain in
elderly with dementia; 2) disproportionate increase in
painful conditions among elderly with dementia; 3)
reflection of the general increase in opioid prescrib-
ing; and 4) use of opioids for indications other than
pain.
First, pain in elderly with dementia has been the
subject of more attention over the past 10–15 years,
with increasing opioid use possibly a reflection of
improved recognition and treatment of pain. In 2000,
however, opioid use was already higher in elderly
with dementia compared with elderly without and has
had a steeper rise. Thus, improved recognition and
treatment of pain is most likely not the only expla-
nation. A second alternative explanation is that our
study population of elderly with dementia had more
pain-causing conditions. When adjusting for painful
conditions and other comorbidities in our logistic
regression analysis, however, elderly with dementia
still had a larger increase in opioid use.
Third, opioid use has increased in the general pop-
ulation [24, 25], making it unsurprising that this is
also the case in elderly with dementia. The increas-
ing opioid use is primarily driven by an increase
in use of transdermal formulations, which were
marketed in Denmark in 1995 (fentanyl) and 2003
(buprenorphine). Previously, it was thought that pain
was undertreated in elderly with dementia [26–28]
which means that the increase in opioid use may
be a reflection of adequate pain treatment. However,
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prevalence and treatment intensity of opioid use was
already higher in 2000 in elderly with dementia com-
pared with elderly without, with a larger increase
in both prevalence and treatment intensity continu-
ing to occur. The Danish Dementia plan from 2010
did not contain adequate guidance on palliative care
including pain relief and psychosocial interventions
to neuropsychiatric symptoms [29], which may be
part of the explanation for the high use in 2000 and
why it continued to increase. In September 2014, we
published our previous study about opioid use among
elderly with dementia [13], which led to a consider-
able amount of debate and the Minister of Health had
to explain how he would handle the matter. The debate
may have stopped the increase in opioid as there was
no further increase after 2013. This indicates that the
general increase in opioid prescribing is not the only
explanation.
Fourth, the increase in opioid use occurred simul-
taneously with a decrease in antipsychotic use. There
has been a marked decrease in antipsychotic use since
2004 due to safety warnings [6–8], public debate,
and educational efforts, but behavioral symptoms still
pose a considerable challenge for family and pro-
fessional caregivers [1, 2]. Naturally, a search for
alternative ways to treat behavioral symptoms has
occurred. Awareness of the fact that pain can lead
to behavioral symptoms in elderly with dementia has
grown in the past 15–20 years [30, 31]. However, pain
is only one of many reasons why elderly with demen-
tia develop behavioral symptoms, which is why a
thorough workup is recommended before prescrib-
ing analgesics to treat these symptoms [32, 33]. Thus,
one could speculate that physicians and caregivers are
overly aware of pain as a cause of behavioral symp-
toms. The apparent effect of opioids on behavioral
symptoms may reflect the sedative rather than the
analgesic effect of opioids. As a result, another pos-
sible explanation for the disproportionate increase in
opioid use in elderly with dementia is that opioids,
to some extent, have replaced antipsychotics in man-
aging behavioral symptoms, despite lack of evidence
for effect of opioids [34].
An important issue is whether opioids are safe to
use in elderly with dementia. Elderly with dementia
have generally been excluded from clinical stud-
ies of opioids, just as a lack of knowledge exists
about the clinical effect on pain and adverse events
associated with opioid use in this patient group. Opi-
oids have been associated with an increased risk of
fall and fracture in the elderly [10] and mortality
in patients with chronic non-cancer pain [11, 12].
In recent years, there has been increasing concern
about the risk associated with opioids in general
[35, 36], and recent guidelines recommend non-
opioid therapy to treat chronic non-malignant pain
[35, 37]. Several warnings have been issued against
using fentanyl patches in non-opioid-tolerant patients
because of serious adverse events and deaths [38]. In a
recent study of tolerability of buprenorphine in nurs-
ing home residents with advanced dementia, 52.3%
discontinued treatment due to adverse events, with
sedation/somnolence being the most frequent, com-
pared with 13.3% in the placebo group [39]. Thus,
the greater increase in opioid use among elderly with
dementia, is a cause for concern.
Strengths and limitations
One of the major strengths of this study was that it
is based on data from the public Danish health care
system, which completely covers the entire Danish
population, making it possible to study real-life pre-
scription patterns over time and eliminating problems
of selection bias. The validity of registered demen-
tia diagnoses at hospitals has previously been shown
to be high [40], but most cases are registered as
unspecific dementia. Dementia is generally under-
diagnosed and potentially undiagnosed cases among
the reference group could lead to an underestima-
tion of differences between elderly with dementia
and elderly without. Furthermore, a limitation is that
information about severity of dementia, diagnosis of
pain and presence/absence of behavioral symptoms is
not available. The Danish National Prescription Reg-
istry records all prescriptions filled at pharmacies and
the information has proven to be accurate [17]. A
limitation, though, is that the exact indication is not
recorded, just as there is no certainty that the patients
consumed the drugs. Another limitation is that the
data does not allow us to distinguish between regular
and as required use, neither does is contain infor-
mation about efficacy of analgesic or antipsychotics
therapy. Our study is a descriptive study, which can
generate hypothesis about drug use, but the design is
not suited to investigate causality.
Conclusion
Use of opioids increased from 2000 to 2015, with a
disproportionate steeper increase among elderly with
dementia despite an already higher baseline in 2000.
The increase in opioid use in elderly with dementia
was mainly due to an increase in strong opioid use,
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but particularly the use of transdermal formulations of
opioids increased dramatically in elderly with demen-
tia. Concurrently, a decrease in antipsychotic use
in elderly with dementia has occurred. The parallel
decrease in antipsychotics raises the issue of whether
opioids, to some extent, have replaced antipsychotics
in managing behavioral symptoms, despite safety
concerns and lack of evidence for effect. As opioid
use is on the rise in several countries, there are reasons
to believe that our findings apply outside Denmark
and should be cause for international concern. We
recommend conducting more research to provide evi-
dence for the benefit and risk associated with opioid
use in elderly with dementia.
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